Nofebran (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes COX‑1 and COX‑2, which reduces the production of prostaglandins that mediate pain and fever. The lowered prostaglandin levels produce analgesic and antipyretic effects, while the drug does not act on opioid receptors.

The dosage of Nofebran is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and clinical response. Healthcare professionals adjust the dose and infusion rate according to standard medical guidelines and individual patient factors.

Safety data for metamizole sodium during pregnancy and lactation are limited, and the product is generally used only when the potential benefit outweighs the risk. Clinicians should evaluate each case carefully and consider alternative therapies when possible.

To order Nofebran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Nofebran (metamizole sodium) is a non‑opioid analgesic that offers rapid pain relief similar to other NSAIDs but with a distinct safety profile, notably a risk of agranulocytosis. Compared with opioid analgesics, it does not cause respiratory depression, while it may be preferred over some NSAIDs when gastrointestinal tolerance is a concern.

Nofebran should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and sterility.

Nofebran is supplied as an injectable solution for intravenous administration. It is typically given by slow IV infusion under medical supervision, allowing the clinician to monitor the patient for any immediate adverse reactions during and after the infusion.

The most serious risks associated with Nofebran include agranulocytosis, which can lead to severe infections, life‑threatening skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and anaphylactic shock. Prompt recognition of symptoms and immediate medical intervention are essential.

Nofebran should be avoided in patients with known hypersensitivity to metamizole or other pyrazolone derivatives, those with a history of severe blood dyscrasias, and individuals with uncontrolled severe infections. Caution is also advised for patients with significant renal or hepatic impairment.